Join the Angelman Community in 40 locations across the US. Whether a walk, 5K, or community event, Angelman Strong is continuing the legacy of connection and support started by the ASF Walks.
Saturday, May 17 in most locations
Find one near you and register to support & celebrate individuals with Angelman syndrome.
ASF funded research advance our understanding of AS and increase the potential for treatment & therapeutics.
FIND OUT MORE
Since her diagnosis, we have relied on the Angelman Syndrome Foundation as a source of information and support.
The Angelman Syndrome Clinic at MGH is a blessing for my adult child. Now we have somebody who really understands our needs.
Amazing things have happened because of the ASF-funded LGIT study from Boston’s MassGeneral Hospital. It was the beginning of a new era for treatments for our children with AS.
Latest press releases, articles and announcements
MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MVX-220, an investigational […]
Read more
In June 2023, Roche announced they would not be moving forward with a clinical trial for rugonersen, an investigational ASO for AS, and would be looking for an external partner to take over the development. Oak Hill Bio has entered […]
Read more
Introducing the Angelman Syndrome Global Community Advisory Board (CAB) As we prepare for International Angelman Day, we are thrilled to introduce the Angelman Syndrome Global Community Advisory Board (CAB)! This remarkable group of parent advocates and expert parents/carers has come […]
Read more
Ultragenyx Pharmaceutical Inc. announced today that the first patient(s) has/have been dosed in the pivotal Phase 3 Aspire study evaluating the efficacy and safety of GTX-102, its investigational antisense oligonucleotide (ASO) for Angelman syndrome. Check clinicaltrials.gov for recruitment status and participation criteria. […]
Read more
